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Abstract
Background: Molecules of the class II major histocompability complex (MHC-II) specifically bind
and present exogenously derived peptide epitopes to CD4+ T helper cells. The extreme
polymorphism of the MHC-II hampers the complete analysis of peptide binding. It is also a
significant hurdle in the generation of MHC-II molecules as reagents to study and manipulate
specific T helper cell responses. Methods to generate functional MHC-II molecules recombinantly,
and measure their interaction with peptides, would be highly desirable; however, no consensus
methodology has yet emerged.
Results: We generated α and β MHC-II chain constructs, where the membrane-spanning regions
were replaced by dimerization motifs, and the C-terminal of the β chains was fused to a
biotinylation signal peptide (BSP) allowing for in vivo biotinylation. These chains were produced
separately as inclusion bodies in E. coli , extracted into urea, and purified under denaturing and non-
reducing conditions using conventional column chromatography. Subsequently, diluting the two
chains into a folding reaction with appropriate peptide resulted in efficient peptide-MHC-II complex
formation. Several different formats of peptide-binding assay were developed including a
homogeneous, non-radioactive, high-throughput (HTS) binding assay. Binding isotherms were
generated allowing the affinities of interaction to be determined. The affinities of the best binders
were found to be in the low nanomolar range. Recombinant MHC-II molecules and accompanying
HTS peptide-binding assay were successfully developed for nine different MHC-II molecules
including the DPA1*0103/DPB1*0401 (DP401) and DQA1*0501/DQB1*0201, where both α and
β chains are polymorphic, illustrating the advantages of producing the two chains separately.
Conclusion: We have successfully developed versatile MHC-II resources, which may assist in the
generation of MHC class II -wide reagents, data, and tools.
Background
MHC molecules control the specificity of the adaptive
immune system. They select peptides from any available
protein in the body – be it from a foreign invader, a trans-
formed cell, or from the protein metabolism of healthy
cells – and present the selected peptides to circulating T
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cells for approval, or rejection, by the immune system.
Two classes of MHC molecules exists, class I and II, differ-
ing with respect to function, cellular distribution and
molecular composition.
In general, MHC class I molecules select peptides derived
from cytosolic proteins and present them to cytotoxic T
cells (CTL's) thereby endowing the immune system with
the ability to examine the cellular integrity of our cells and
respond to any perceived intracellular threat. Serving this
function, MHC class I molecules are expressed on virtually
all nucleated cells. Structurally, MHC class I molecules
consist of a three-domain transmembrane heavy chain
non-covalently associated with a light chain. The two
outer domains of the heavy chain form a peptide-binding
cleft. Bound peptides are deeply embedded in the MHC
and both ends of the cleft are closed. This tends to restrict
binding to peptides of limited length (e.g. 8–12 amino
acids).
In contrast, MHC class II molecules select peptides
derived from endocytosed proteins and present them to T
helper cells (Th) thereby allowing the immune system to
examine the extracellular space for the presence of pro-
tein-based pathogens. MHC class II molecules are
expressed on cells involved in orchestrating immune
responses; typically cells of the immune system itself (pro-
fessional antigen presenting cells and activated T cells)
and on activated tissues such as endothelia etc. MHC-II
molecules consist of two transmembrane chains each
with two domains. Despite this difference in how the
chains and domains of the molecules of the two MHC
classes are organized, there is a striking similarity in the
structural features of the two classes of MHC molecules.
The outer domains of MHC class II composed of the α1/β1
heavy chain domains forming a peptide-binding cleft,
which in many respects resemble that of the outer
domains of the MHC class I composed of the α1/α2 heavy
chain domains. The peptide-binding cleft of MHC class II
differs from that of MHC class I primarily in being open at
both ends allowing peptides to extend out of the cleft. In
general, MHC class II can accommodate longer peptides
than MHC class I.
In most vertebrates, the MHC region is polygenic and
extremely polymorphic. Thus, the specificities of peptide
selection and presentation vary from individual to indi-
vidual effectively reducing the risk of population-wide
pathogen escape. In the human, MHC class II encom-
passes three isotypes, HLA-DR, -DQ and -DP. The num-
bers of registered human class II α and β heavy chain
proteins are currently (as of January 2009): 2 and 556 for
DRα and β, respectively; 25 and 69 for DQα and β, respec-
tively; and 16 and 115 for DPα and β, respectively. For
DR, the polymorphism of the peptide-binding cleft is
determined solely by the β chain. For DQ and DP, pairing
of α and β chains determine the polymorphism of the
peptide-binding cleft. This potentially lead to as many as
1725 different DQ specificities, and 1840 different DP
specificities,.
Here, we have used a disulphide-assisted refolding princi-
ple and dimerizing modules to assemble soluble, func-
tionally empty, MHC-II heterodimers from α and β chain
proteins produced independently in E. coli . For all nine
MHC-II molecules examined here (six HLA-DR, one HLA-
DP, one HLA-DQ, and one mouse I-Ed), we successfully
managed to generate functional recombinant MHC-II
molecules showing specific peptide binding. Refolding
was quite efficient; in some cases yields of more than 20%
were obtained. Efficient in vivo biotinylation enabled
streptavidin-based peptide-MHC-II interaction assays
including several sensitive and high-throughput binding
assays. These approaches to generate MHC class II mole-
cules, and analyze their function, might meet the chal-
lenge of addressing the polymorphism of the MHC class
II system.
Methods
Cloning of HLA constructs
All genes were generated synthetically by consecutive
overlap extension PCR reactions and QuikChange muta-
tions, or purchased from GenScript, cloned into the
pET28a+ (kanamycin resistance, IPTG induction) vector
and transformed into DH5α E. coli cells using standard
molecular biology techniques. The intended DNA
sequences were verified by DNA sequencing (ABI3100,
Perkin Elmer). Plasmids were purified and transformed
into BL21(DE3) E. Coli cells for protein production. To
allow for in vivo biotinylation, BL21(DE3) were co-trans-
formed with a pASYC (chloramphenicol resistance, IPTG
inducible) vector with the gene encoding the BirA bioti-
nylation holoenzyme. Clones, which produced the fusion
product upon induction with IPTG, were identified and
used for large-scale expression. The full length sequences
of produced protein constructs can be seen in additional
file 1, Figure 1.
Expression of HLA class II α and β chain proteins in E coli 
inclusion bodies
All α chains were produced in shaker bottles using an
auto-induction method described by Studier [1].
All β chains were expressed in a fermentor using IPTG
induction as previously described [2] (except for
DPB1*0401, which was produced by auto-induction).
Briefly, cells were expanded overnight and used to seed a
2.5 L Labfors® fermentor. Cells were grown at 37°C to an
OD of 25. The temperature was then raised to 42°C and
IPTG added to a concentration of 1 mM. For in vivo bioti-Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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nylation 0.5 mM d-Biotin was added at the time of induc-
tion. After 3 hours, cells were processed at 2.3 kBar in a
cell disrupter (basic Z, Constant Systems Ltd Daventry,
UK). Using centrifugation (Sorvall RC6, 17,000 g, 30 min,
4°C), the inclusion body pellet was washed twice in 0.5%
NP40, 0.1% DOC in PBS.
Purification of denatured HLA α and β chain proteins
The washed pellet was dissolved overnight in 200 ml 8 M
Urea, 25 mM Tris, pH 8, and any remaining DNA was pre-
cipitated with streptomycin sulphate (10 g/L). After cen-
trifugation (Sorvall RC6, 17,000 g, 30 min, 4°C), the
denatured protein solution was applied to an 800 ml Q
Sepharose Fast Flow column. The column was washed
with 8 M Urea, 25 mM Tris, pH 8 (Buffer A), and eluted
with a two-step gradient (0–30% in 3 column volumes
(CV), 30–100% in 1 CV of buffer B (A + 1 M NaCl). Frac-
tions containing proteins of interest, as determined by
SDS-PAGE, were pooled and concentrated to 100 ml
using 10 kDa cut-off tangential ultrafiltration (Vivaflow
200, Vivascience AG, Göttingen, Germany). The concen-
trate was applied to a 3.5 L Superdex 200PG gel filtration
column (GE Healthcare) and eluted with 8 M Urea, 25
mM Tris, 150 mM NaCl, pH 8. Fractions containing dena-
tured monomer were pooled, frozen at -20°C, and used
for further experiments.
Radiolabelling peptide with 125I
For radio-iodination purposes the influenza hemaggluti-
nin peptide, HA306–318 (PKYVKQNTLKLAT), was extended
N-terminally with a tyrosine generating (Y)HA306–318. The
peptide was 125I iodinated using a chloramine method [3]
to a specific activity of approximately 75 Ci/mmol corre-
sponding to 500 cpm/μl at a final working concentration
of 3 nM. We noted that only 30–40% of this particular ref-
erence peptide could bind regardless of how much MHC
was added. We speculated that iodination of the tyrosine
in the first anchor position of the HA306–318 peptide might
influence binding. Indeed, changing this tyrosine to phe-
nylalanine, another accepted first anchor residue,
increased the relative amount of radioactivity that could
be incorporated into MHC complexes (data not shown).
MHC class II binding of radiolabelled peptide measured by 
gel filtration
Equimolar concentrations of denatured DRA*01011–191
and DRB1*01011–198 chains (4 μM each in 8 M urea) were
diluted 50 times to a final concentration of 80 nM MHC.
The refolding buffer consisted of 25% v/v glycerol, 50 mM
Tris, pH8, PMSF (11.4 μg/ml), pepstatin (3.3 μg/ml),
TLCK (3.3 μg/ml) and TPCK (3.3 μg/ml) – and in some
cases (see below) further additives. Just before use, the
refolding buffer was supplemented with 3 nM 125I labeled
(Y)HA306–318 peptide. The reaction mixture was incubated
for 24 h at 18°C. After incubation, free and MHC-bound
125I labeled peptide was separated by gradient centrifuga-
tion spun column chromatography as previously
described [4], and counted by gamma spectrometry (Pack-
ard Cobra 5010). The fraction of bound peptide was cal-
culated as (peptide bound/(peptide bound + peptide
free)).
Optimizing refolding and peptide binding conditions
Various buffer compositions were tested in an attempt to
optimize refolding and peptide binding: Glycerol (range 0
to 25% v/v), Arginine (0 to 500 mM), Urea (0 to 1000
mM), Sucrose (0 to 500 mM), Sodium Chloride (0 to 500
mM), N-Laurylsarcosin (0 to 1,5% w/w), Dextran (0 to
0.5% w/w), Pluronic acid F68 (0 to 0.5% w/w), Deoxy-
cholate (DOC) (0 to 0.5% w/w), NP40 (0 to 0.5% w/w),
PEG6000 (0 to 0.5% w/w), PEG20000 (0 to 0.5% w/w),
beta octylglycoside (0 to 0.5% w/w), and Tween20 (0 to
0.5% w/w). Similarly, various pH conditions were tested
using a refolding buffer composed of protease inhibitors
(as above), 25% v/v Glycerol, and 50 mM Tris/Morpho-
line Ethane Sulphonic acid (MES) adjusted to pH values
between 5 and 10. After 24 h incubation at 18°C, the sam-
ples were analyzed by spun column chromatography (as
above).
Time and temperature conditions were tested using a
refolding buffer (as above) adjusted to pH 8. Aliquots
were distributed into PCR tubes and incubated at 10, 20
or 30°C with temperatures controlled by a PCR thermocy-
cler. At different time points, tubes were removed from
the thermocycler and stored at -20°C until analyzed by
spun column chromatography (the high glycerol content
of the buffer allowed this kind of cryopreservation).
Unless otherwise stated, the following optimal MHC class
II refolding and peptide binding conditions were subse-
quently chosen: a refolding buffer composed of protease
inhibitors (as above), 0.01% Pluriol F68, 25% v/v Glyc-
erol, and 50 mM Tris/Citrate pH 6–7.5, and reaction mix-
tures were incubated for 24 h at 18°C.
Refolding and purification of MHC class II standards
2 ml of 10 μM denatured MHC II α and β chain (DR1:
DRA*01011–191/DRB1*01011–198(C30S); DR2a:
DRA*01011–181/DRB5*01011–190; DR4: DRA*01011–181/
DRB1*04011–190) was diluted drop wise into 60 ml
refolding buffer pH 7.5 containing 2 μM HA306-318H6
(PKYVKQNTLKLATHHHHHH). After 48 h incubation at
18°C, the refolding mixture was loaded onto a 6 ml Ni2+
charged IDA column. The column was washed with PBS
(Buffer A) until the UV280 signal reached baseline fol-
lowed by a two segment gradient (0–20% in 5 CV, and
20–100% B in 2 CV) with buffer B (PBS supplemented
with 250 mM Imidazole). Fractions were collected and
analyzed by reducing SDS-PAGE.Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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MHC class II binding measured by ELISA
Monoclonal murine antibodies LB3.1[5,6] (mouse anti-
DR α chain), D1.12 [7] (anti-DR), L243 [8] (anti-DR α
chain) G8 [9] (anti-DR), 9.3F10 [6,10] (anti-DR, DQ),
2.06 [11] (anti-DR), B7/21 [6] (pan specific-DP), and
14.4.4S [12] (anti I-Ed) were purified from culture super-
natants (L243 and 14.4.4S), or ascites, by anion exchange
or protein A chromatography.
Appropriate MHC class II standards were serially diluted
in PBS and added to a Streptavidin plate (NUNC, Den-
mark), which had been blocked in 5% skim milk powder
(SMP). After 1 h incubation at RT, the plate was washed 3
times in PBS with 0,01% Tween-20, and monoclonal anti-
MHC class II antibodies were added (50 μl/well of a 10
μg/ml dilution in PBS with 2% SMP). After 1 h incubation
at RT, the plate was washed 3 times in PBS with 0.01%
Tween-20, and HRP conjugated goat anti-mouse antisera
(A9917, Sigma Aldrich) was added (50 μl/well of a 1/
12,000 dilution in PBS with 2% SMP). After 1 h incuba-
tion at RT, the plate was washed 3 times in PBS with
0.01% Tween-20, and 3,3',5,5'-tetrametylbenzidin (TMB)
"One-Step Substrate" (DAKO) was added (50 μl/well).
After 30 min incubation at RT in the dark, sulfuric acid (50
μl/well of a 0.3 M solution) was added to stop the color
reaction, and the plates were read at 450 nm in a Power-
wave microplate spectrometer (Bio-Tek instruments).
To identify optimal concentrations of MHC class II α and
β chains (DR1: DRA*01011–191/DRB1*01011–198(C30S);
DR2a: DRA*01011–181/DRB5*01011–190; DR4:
DRA*01011–181/DRB1*04011–190), six titrations of α
chains, and eight of β chains, were diluted in 8 M Urea, 25
mM Tris, pH 8; and the two titration series were combined
to create a checkerboard of 48 different combinations of
α/β concentrations. These were further diluted 33 times
into a refolding buffer pH 6–8 with, or without, 2 μM
HA306–318. After 24 h incubation at 18°C, the plates were
developed in an ELISA (as described above) using appro-
priate anti-MHC class II monoclonal antibodies as detec-
tion antibodies. Signals and signal/noise ratios were
calculated for each combination of α/β concentrations.
Using optimal α/β concentrations, denatured MHC class
II α and β chains were diluted into refolding buffer with a
titration of test peptide, and incubated for 48 h at 18°C.
The ELISA was used to measure the resulting peptide-
MHC class II complexes. The absorbance values (450 nm)
were graphed vs. the concentrations of peptide offered,
and the data analyzed by GraphPad Prism as described
below.
MHC class II binding measured by Luminescent Oxygen 
Channelling Immunoassay (LOCI)
LOCI (marketed by Perkin Elmer as AlphaScreen) is a two-
bead assay system: donor beads contain a photosensitizer
compound, which upon illumination with laser light at a
wavelength of 680 nm converts ambient oxygen to
energy-rich, short-lived singlet oxygen; and acceptor
beads, which can respond to singlet oxygen with a lumi-
nescence/fluorescence cascade leading to an amplified sig-
nal in the 520–620 nm range. The oxygen released by a
donor bead will only excite acceptor beads within a dis-
tance of ~200 nm, and this allows a proximity-based
homogenous assay quantifying interacting biomolecules.
We have recently described a LOCI-based HTS assay for
measuring peptide-MHC class I interaction [13].
Here, donor beads coated with streptavidin, and acceptor
beads for custom protein coupling were both purchased
from PerkinElmer. Specific anti-MHC class II monoclonal
antibodies were coupled to acceptors beads following the
manufacturers recommendation (L243 for HLA-DR; B7/
21 for HLA-DP; 9,3F10 for HLA-DQ; and 14-4-4 for I-Ed).
Peptide-MHC class II reaction mixtures were generated
and incubated 48 h at 18°C as described above for the
ELISA. The peptide-MHC class II reaction mixtures were
then mixed with equal volumes (12–25 μl) of a solution
containing streptavidin donor beads and anti-MHC-II
monoclonal antibody conjugated acceptor beads (both at
10  μg/ml in PBS containing 0,1% Pluronic F68). The
plates were incubated for 18 h at 18°C and then read in
an ENVISION reader (Perkin Elmer). As for the ELISA, the
optimal combination of α and β chain concentrations was
identified in pilot experiments. Then, peptide titrations
and the resulting peptide-MHC class II formations were
determined in a LOCI assay calibrated with a known MHC
class II standard.
A LOCI-based competitive assay was also developed. In
this assay, a binding reaction was set up between a trace
concentration of a biotin labeled agonist peptide (biotin
attached via a PEG linker to HA306–318) and non-bioti-
nylated MHC-II molecules. For many HLA-DR molecules
one could use low nanomolar (in casu 4 nM) concentra-
tions of agonist peptide. The resulting agonist-MHC-II
interactions were developed using a LOCI assay as
described above. Once an agonist-MHC-II interaction
assay had been established, competition assays using titra-
tions of any test peptide of interest could be conducted.
Peptide affinity calculations
The formation of peptide-MHC complexes was calculated
from LOCI generated data, which had been calibrated
using standard curves obtained with purified peptide-
MHC complexes of known concentrations.
For direct binding experiments, the concentrations of pep-
tide-MHC class II complexes formed were graphed versus
the concentrations of peptide offered, and analyzed by
non-linear regression (GraphPad Prism). The peptide
concentration resulting in half saturation, the half maxi-Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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mal effective concentration (EC50), was estimated by fit-
ting the experimental data to the equation Y = Bmax*X/
(KD+X), where Y is the concentration of peptide-MHC-II
complexes formed and X is the concentration of ligand
(peptide) offered. The EC50 approximates the KD as long as
the receptor concentration used is less than the KD thus
avoiding ligand depletion.
For the competitive binding assay, the concentrations of
peptide-MHC class II complexes formed were graphed
versus the logarithm of the concentrations of inhibitory
peptide used, and analyzed by non-linear regression
(GraphPad Prism). The peptide concentration resulting in
half inhibition, the half maximal inhibitory concentra-
tion (IC50), was estimated by fitting the semi-log trans-
formed experimental data to the equation Y = Bottom +
(Top-Bottom)/(1+10^(X-Log(IC50))), where Y is the con-
centration of agonist-MHC-II complexes formed, X is the
logarithm of the concentration of inhibitor offered, Top is
the upper plateau of the curve (i.e. without inhibitory
peptide) and Bottom is the lower plateau of the curve (i.e.
with saturating concentrations of the inhibitory peptide).
The IC50 approximates the KD of the inhibitor peptide as
long as the receptor concentration used is less than the
KD's of both the agonist and inhibitor peptides [14].
Results
Design of MHC class II α and β chains
HLA class II α and β chain polypeptide sequences were
obtained from the IMGT/HLA Sequence Databasehttp://
www.anthonynolan.org.uk/HIG/. The I-Ed α and β chains
were obtained from the Swiss-Prot database http://
beta.uniprot.org/; accessions P01904 and P01915, respec-
tively. Gene sequences were codon-optimized for E coli
expression and truncated to remove the transmembrane
regions. Most chains were produced in two different trun-
cations; a short and a long version of the α chain compris-
ing amino acids 1–181 and 1–191, respectively; and a
short and a long version of the β chains comprising amino
acids 1–190 and 1–198, respectively (see additional file 1,
Figure 4).
We have previously demonstrated how unpaired cysteines
can seriously reduce functional yield [15,16]. Unpaired
cysteine residues in positions 30, 47 and 123 of
DRB1*0101, DQA1*0501 and DPA1*0103, respectively,
were therefore mutated to serine. Position 30 of
DRB1*0101 and 47 of DQA1*0501 is located in the bind-
ing groove and might affect the peptide binding specifi-
city, albeit a cysteine to serine might be considered a
conservative substitution in an MHC context. Position
123 of DPA1*0103 is located in the second domain and
would not be expected to influence the specificity of pep-
tide binding.
Initially DQA1*0501 expressed poorly in bacteria, how-
ever N-terminal fusion of the natural histidine affinity tag
(HAT) increased expression.
To assist in α/β chain assembly, a pentaglycine linker fol-
lowed by the fos and jun leucine zipper was added to the
C-terminal of the α and β chain, respectively. To allow for
specific enzymatic biotinylation, the jun leucine zipper of
the β chain was further extended by a triglycine linker and
a biotinylation substrate peptide [17]. Using the E. coli
GrpE chaperone to direct dimerization, an alternative α/β
chain assembly system was successfully developed (see
additional file 1).
In all cases, the β chains were produced with a C-termi-
nally added biotinylation substrate peptide (BSP) allow-
ing  in vivo biotinylation using co-induced BirA
holoenzyme to couple d-biotin specifically to the BSP
sequence [18].
The resulting polypeptide sequences are shown in addi-
tional file 1, Figure 1.
Expression and Purification of MHC class II α and β chains
After induction, the recombinant proteins were contained
in bacterial inclusion bodies. Inclusion bodies were proc-
essed by high-pressure cell disruption, harvested and
washed by centrifugation. The recombinant proteins were
extracted from the inclusion bodies into 8 M Urea and
purified by Q Sepharose anion exchange chromatograhy
followed by Superdex 200PG gel filtration chromatogra-
phy. Pure preparations were obtained as demonstrated by
non-reducing SDS-PAGE (exemplified for DRB5*0101,
Figure 1A). The yields were typically 50–70 g/L for autoin-
duction and 80–120 g/L for IPTG induction of pure α and
β chain, respectively.
Denaturing, but non-reducing, conditions were main-
tained throughout the extraction, purification and subse-
quent storage procedures. We have previously described
that a large fraction of MHC class I molecules produced in
this manner is correctly oxidized and refolds very effi-
ciently [2,16,18]. Being structurally related to MHC class
I, we reasoned that MHC class II molecules might also be
produced in a highly active, pre-oxidized form. Indeed,
non-reducing SDS-PAGE showed slightly smeared MHC
bands (Figure 1A), or in some cases even distinct and
closely appositional bands, which disappeared upon
reduction and generated a single band (Figure 1C). Over-
loading the SDS-PAGE only visualized few contaminants;
mostly high-molecular aggregates of MHC since they dis-
appeared upon reduction while the staining of the MHC
band increased (Figure 1C). Storage at -20°C for a year
gave rise to modest formation of high-molecular weight
aggregates and complexes (Figure 1A), which disappearedImmunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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upon reduction. Together these data suggest that our prep-
arations predominantly contained MHC proteins, and as
expected consisted of different di-sulfide isomers.
We have previously reported that in vivo enzymatic bioti-
nylation can be very efficient. For a large cohort of MHC
class I molecules we routinely obtained biotinylation effi-
ciencies in excess of 90–95%. Similar high biotinylation
efficiencies were obtained for MHC class II as illustrated
by a SDS-PAGE gel-shift assay where an excess streptavi-
din led to a mobility shift of almost the entire population
of monomers (Figure 1B).
Characterization of peptide-MHC class II complexes
A high-affinity binding peptide with a hexa-histidine
affinity tag was used to purify functional DRA*0101/
DRB5*0101 (DR2a) heterodimers. Purified denatured
DRA*01011–181 and DRB5*01011–190 were diluted drop-
Purification of MHC II and refolding of complexes Figure 1
Purification of MHC II and refolding of complexes. (A) Non reducing gel showing purification of urea denatured 
DRB5*0101. IB: urea denatured inclusion bodies after fermentation. AIEX: Purity after ion-exchange on Q-Sepharose FastFlow. 
GF: Purity after gel filtration on Superdex200, this is the final product from the purification. Though pure, the MHC band 
seems to consist of several sub bands each representing an oxidative isomer of the molecule. 1 Year: Same product after 1 year 
at -20°C. Note the formation of higher molecular weight aggregates (HMWA), and a more concentrated MHC band. (B) Bioti-
nylation test, gel shift assay of DRB1*0401. Without streptavidin MHCbiotin travels as a monomer, addition of an excess of 
streptavidin causes nearly all MHCbiotin to shift to a position corresponding to a 1:1 complex with streptavidin, without MHC-
biotin streptavidin travels as a monomer. In most cases a nearly quantitative biotinylation could be achieved. (C) Reducing and 
non-reducing SDS-PAGE of DRA*0101, DRB1*0101, DRB5*0101 and DRB1*0401. (D) IMAC purification of DR2a refolded in 
the presence of a histidine tagged HA306-318H6 peptide and eluted by an imidazole gradient. Fractions were collected and ana-
lysed by reducing SDS-PAGE (samples boiled). Peak I: Run through Peak II: empty α and β chain binding with moderate affinity 
to Ni2+ column Peak III: Elution of MHC II complex by imidazole. (E) Non-reducing SDS-PAGE analysis of DR1, DR2a and DR4 
complexes refolded and purified as in D. Note the SDS stability of DR1 and DR4. The final yields were 12, 23 and 14%, respec-
tively.Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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wise into a refolding buffer containing a histidine-tagged
influenza peptide, HA306-318H6, incubated for 48 h at
18°C, and then purified by immobilized Ni2+ affinity
chromatography (Figure 1D). Samples were taken from
each fraction, reduced and boiled, and analyzed by SDS-
PAGE (Figure 1D insert). Since empty α and β chains
bound with low affinity to the Ni2+ column, a two-seg-
ment gradient was used to separate empty chains from
complexes. The chromatogram therefore showed two elu-
tion peaks, which both contained MHC molecules
(labeled II and III in Figure 1D and insert).
However, the late peak was only seen when the HA306-
318H6 peptide was present during refolding, whereas the
early peak was generated even in the absence of the pep-
tide (data not shown). To further support that the late
peak contained relevant peptide-MHC class II complexes,
a non-reducing SDS-PAGE gel was performed with and
without boiling the samples. It has previously been
shown that many peptide-MHC class II complexes are
resistant to SDS-PAGE as long as they are not boiled [19].
The hexa-histidine tagged HA306-318H6 peptide was used to
generate and purify three different DR molecules, DR1,
DR2a and DR4, as described above, and samples from the
late peak subjected to boiling and SDS-PAGE. For all three
DR molecules, the late peaks contained SDS-resistant, but
heat sensitive, complexes (Figure 1E), whereas the early
peaks did not contain SDS-resistant complexes (data not
shown). We conclude that our recombinant MHC-II mol-
ecules exhibit the known peptide-dependent SDS-sensi-
tivity of native MHC-II molecules.
We also noted that the folding efficiencies of our recom-
binant DR1, DR2a and DR4 molecules interacting with
the Ha306-318H6 peptide, under the conditions of these ini-
tial experiments, were quite high: 12, 23, and 14%,
respectively.
Development of a peptide-MHC class II binding assay
To optimize the refolding conditions of MHC-II mole-
cules, we initially employed a robust and easily interpret-
able assay involving binding of radioactively labeled
peptide to MHC class II molecules. Briefly, a dose-titration
of equimolar denatured DR1 α and β chains were diluted
into refolding buffer containing 3 nM of a 125I labeled ref-
erence peptide, (Y)HA306–318, and incubated (24 h,
18°C). Binding was determined by gradient-centrifuga-
tion spun column gel-filtration separating bound vs. free
peptide [4]. An MHC class II dose-dependent binding was
observed with a half maximal binding occurring at
approximately 20 nM (Figure 2A). In an attempt to opti-
mize the binding reaction, we tested the effects of various
commonly used refolding additives such as arginine, glyc-
erol, sucrose, detergents, alcohols etc. Glycerol was found
to have the a pronounced positive impact upon refolding
yields (Figure 2B); no other investigated refolding addi-
tive had any significant positive effect upon refolding and
many had a negative effect (additional file 1, Table 1). The
positive effect of glycerol upon MHC class II folding has
been noticed by others [8,20-22]. Refolding of proteins
can be very pH dependent and the effect of pH was there-
fore also examined. The optimal pH for refolding and
incorporation of radio labeled (Y)HA306–318 was found to
be around pH 7–8 (Figure 2C). Then, the kinetics of pep-
tide binding to de novo diluted recombinant MHC class II
α and β chains at different temperatures were investigated.
The rate of peptide complex formation was found to be
highly temperature dependent (Figure 2D). Steady state
bindings were reached after 8, 11 and 48 h incubation at
30, 20, and 10°C, respectively. For all temperatures, a
decline in bound peptide was observed for incubation
periods longer than 20–30 h. This is probably due to the
stability of one or more of the assay components being
compromised during long-term incubation.
Competition experiments were performed to ascertain
that the observed peptide-MHC class II bindings were sat-
urable and specific. Increasing concentrations of compet-
ing peptide were added to a reaction involving binding of
125I labeled (Y)HA306–318 to DR1. The resulting binding
was measured in the spun column assay and depicted as
an inhibition curve (Figure 3). Using GraphPad Prism,
non-linear fittings of the data were performed in all cases
obtaining regression coefficients better than 0.99. IC50 val-
ues could be calculated. The HA306–318, the Invariant chain
(positions 97–120, the CLIP peptide), and the Invariant
chain (positions 73–208), were all good binders to DR1,
whereas a C-terminal Invariant chain fragment devoid of
CLIP (pos 118–208) was a poor binder. The fragment was
previously shown to interact with empty HLA-DR1 mole-
cules, augmenting rather than blocking binding of pep-
tide [23].
Thus, using isolated recombinant MHC class II α and β
chains it is possible to obtain specific peptide-MHC class
II interaction, and measure the affinity of interaction.
Subsequent binding experiments were conducted with
pre-oxidized MHC-II chains diluted into a refolding
buffer containing peptide and 25% glycerol, 50 mM Tris/
Citrate (or MES), a protease inhibitor cocktail, 0.01%
pluronic acid F68, pH 8. This reaction mixture was incu-
bated for 24 h at 18°C, and then analyzed for complex
formation.
Efficient refolding of pre-oxidized, denatured MHC-II 
proteins
The above peptide-binding assay was used to investigate
the basic premise of our approach: that pre-oxidized MHC
class II molecules refold more efficiently than fullyImmunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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reduced MHC class II molecules. SDS-PAGE analysis of
reduced vs. non-reduced α and β chain proteins clearly
demonstrated that pre-oxidized species are present in the
non-reduced protein preparations (Figure 4A). Prepara-
tions of denatured β chain proteins were reduced with
graded concentrations of DTT, and then diluted into an
excess refolding buffer containing various redox pairs as
well as non-reduced denatured α chain and radiolabeled
(Y)HA306–318 peptide, and incubated. The resulting com-
plex formation was analyzed by spun column gel filtra-
tion as described above. Whereas the pre-oxidized species
were highly active with respect to peptide binding, expos-
ing the denatured β chain proteins to reduction with as lit-
tle as 0.6 mM DTT lead to a significant loss of peptide-
binding capacity, and none of the tested concentrations of
redox pairs could regain full peptide-binding capacity
(Figure 4B)
High-throughput screening assays of peptide-MHC class II 
binding (ELISA)
We have recently generated a quantitative ELISA assay for
measuring peptide-MHC class I interaction [24]. In this
Initial optimization of DR1 refolding Figure 2
Initial optimization of DR1 refolding. DR1 refolding was determined using a radioactive peptide and spun column separa-
tion of free and HLA-DR1 bound peptide. Y-axis shows the relative amount of radioactive peptide bound in each experiment. 
(A) Titration of equimolar concentrations of urea denatured DR1 α and β chain into a refolding buffer containing 3 nM 125I 
labelled (Y)HA306–318 peptide. In experiments B-D, the DR1 concentration used was at 80 nM. (B) Titration of Glycerol from 
25 to 0.1%(v/v). (C) Impact of pH on DR1 complex formation. (D) Kinetic of DR1 complex formation at three different tem-
peratures (black square, grey line) 10°C, (triangle, dotted line) 20°C and (black circle, black line) 30°C.I
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Table 1: Affinity measurements using LOCI assay.
DR1GrpEa
Kompb
DR2a
Kompb
DR2a pH6 DR3 DR4 DRB1*0813 DRB3*0301 DQA1*0501 
DQB1*0201
DP401 I-ED Reference
Designation Sequence IC50
(nM)
IC50
(nM)
nM nM nM nM nM nM nM nM
MBP FLYGALLLA 3921 NB NB NB NB NB N.D N.D 34 NB [26]
TERT572Y YLFFYRKSV 4287 NB 2648 NB 1593 95 N.D N.D NB 322
Flu PR8 derived FMYSDFHFI 642 1018 637 NB 1130 NB N.D N.D 1 NB [27]
Pox.o42.con A2 FLIDLAFLI NB 4276 NB NB NB NB NB NB 179 NB
Pox.o42.con.im. A2 RMIAISAKV 1464 1985 1647 516 NB 267 1259 NB NB NB
Brucella WMARRHAER NB NB NB NB NB 224 NB NB NB 6
Salmonella MMAWRMMRY 7 25 18 1709 68 28 1426 4318 NB 837
Flu HA1194-202 IVFMWAIHH 42 529 167 NB NB 276 NB NB NB NB
Hantaan FMSRKLHRY NB 2552 NB 279 NB 21 NB NB 3
Oxytocinase271 YEKKYFAATQFEPLAARL 5 29 6 38 6 38 33 1090 1 NB [79] 
(DP401)
Thyroid peroxidase YIDVWLGGLAENFLPY 605 691 2138 NB NB NB 3184 564 602 NB [6]
No nat. source YPFIEQEGPEFFDQE 1279 NB NB 289 3972 NB 3228 648 NB NB [6]
Hepatitis B YLCQVFADATPTGWGL 1850 NB 3703 69 18 2988 2058 1335 13 NB [6] 
(DR3, DR4)
Plasmodium 
Falciparum
YILLKKILSSRFNQM 7 2 4 32 94 4 1 NB 1 20 [28](DR1, 
DR2a, DR4)
No natural source YILFLVKMNALRRLPV 10 20 5 39 ? 78 3 NB 45 582 [28] (DR1, 
DR2a, DR4)
Hepatitis B VGNFTGLYSSTVPVF 3 31 102 1414 632 2892 9 635 NB NB
Influenza PLKAEIAQRLEDV 50 41 65 134 2678 NB 11 NB 2091 NB [29] 
(DR1, DR2a)
HIV PIVQNIQGQMVHQ 71 852 447 471 NB NB 23 NB NB NB [30](DR1)
HepatitisB PDRVHFASPLHVAWR 5 26 8 6 881 39 3 2807 124 NB
Clostridium tetanus QYIKANSKFIGITE 18 11 22 30 432 29 1 NB 56 1501 [29] 
(DR1, DR2a)
No nat. source KILEPFRKYTAFTIP 10 1 16 18 1600 11 1015 1542 30 2198 [34] (DR2a)
Hepatitis B AFSYMDDVVLGAKSV 215 3382 1721 87 26 2753 764 2039 NB NB
Mycobact leprea GVTYEIDLTNKN NB NB NB 4346 2548 NB NB NB NB NB [6] (DR4)
Murine β2m IQMLKNGKKIPKVEMS 1232 3 6 21 NB 73 70 NB NB 117 [31] (I-Ed)
Lambda repressor YLEDARRLKAIYEKKK 2999 34 87 1098 3120 136 NB NB NB 184 [31] (I-Ed)
6xH Lambda 2(315) HHHHHHIEGRFAALWF
RNHFVFGGGTK
4 20 5 882 11 8 1198 NB 2 26 [32]
6xH Influenza A 
(PR8) HA 109–119
YHHHHHHIEGRSFERFEI
FPKE
325 23 9 1429 1869 181 1528 3913 1 984 [33]
CLIP 6xH LPKPPKPVSKMRMATPLL
MQALPMYHHHHHH
11 1 1 1 2 1 2 2 4 1 2 3
CLIP YLPKPPKPVSKMRMATPL
LMQALPM
11 1 1 2 2 1 3 8 1 4 7 2
HA306-318 YKYVKQNTLKLAT 7 2 10 13 8 11 4 NB NB 25 Most DR
Values represent an average of 2–4 measurements. Affinity measurements higher than 5000 nM were categorized as non-binders (NB). N.D: Not determined. a: The DR1 allele used for these 
measurements was produced as a construct comprising amino acids 1–181 and 1–190 of α and β chain respectively fused C terminally to the dimerizing nucleotide exchange factor GrpE (see 
additional file 1), this construct was not biotinylated and used in the LOCI competition assay. b: Determined using competitive LOCI assay. The reference column also states the MHC alleles 
known to bind the peptide.Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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assay, titrations of peptide and a fixed low concentration
of refolding MHC molecules are co-incubated. The con-
centrations of the resulting complexes are determined,
and it is possible to calculate the KD values directly from
the saturation curves. An important advantage of this
approach is that there is no need to identify a reference
peptide for each MHC to be addressed. However, this type
of assay relies on the identification of a conformation-
dependent MHC class II-specific antibody capable of dis-
criminating between empty and peptide-loaded com-
plexes.
To construct a quantitative sandwich ELISA for HLA-DR
molecules, we decided to take advantage of our MHC class
II molecules being biotinylated. Streptavidin coated plates
were used to capture biotinylated HLA-DR molecules. A
panel of anti-MHC class II antibodies were tested as detec-
tion antibodies using a refolded and purified biotinylated
peptide-DR1 complex as target (additional file 1, Figure 3)
The monoclonal anti-DR antibodies LB3.1, D1.12, L243
and G8 all yielded reasonable signals and were subse-
quently tested for their suitability as a detecting antibody.
Since the final assay would be based upon the correct pair-
ing and refolding of separate MHC class II α and β chains,
each potentially refolding with their own efficiency, it was
important to determine the optimal concentration of each
chain needed to generate peptide receptive complexes.
Two-dimensional titrations were performed using pre-
oxidized denatured α and β chains diluted to each their
specified concentration and incubated in the presence, or
absence, of an excess of binding peptide. After 48 h incu-
bation at 18°C, the samples were analyzed in an ELISA
using streptavidin as capture reagent, and L243, D1.12,
LB3.1, or G8 as detection antibodies. An example of DR4
complex formation analyzed using L243 as the detection
antibody is shown in Figure 5. For each of the 48 combi-
nations of MHC class II α and β chains concentrations a
signal (+ peptide, Figure 5A) and the corresponding noise
(-peptide, Figure 5B) was determined, from these values a
signal to noise ratios could be calculated (Figure 5C). In
this case, final concentrations of 31 nM α and 1 nM β
chains gave the highest signal to noise ratio. In a similar
way, optimal concentrations were determined for other
DR molecules (data not shown). The four selected anti-
bodies were compared using these optimal MHC class II α
and β chain concentrations to generate the different DR
complexes in the presence, or absence, of binding peptide.
Overall, L243 gave the best signal to noise ratios for the
DR proteins tested; D1.12 and LB3.1 gave less discrimina-
tory power; and G8 gave no or very little discriminatory
power (the latter is perhaps not surprising as G8 is specific
for the superantigen binding site [9]). L243 recognizes an
epitope on HLA DR α chain [25] and has previously been
used in DR peptide binding assays [8]. In subsequent DR
experiments, L243 was used as a detection antibody. In
the same manner, suitable antibodies for peptide-depend-
ent DQA1*0501/DQB1*0201 (in casu 9,3F10) DP401 (in
casu B7/21) or murine I-Ed (in casu 14.4.4s) complex for-
mation were identified.
In an attempt to reduce the background further, different
detergents, a chaotrope (urea) or an elevated temperature,
were attempted included in the detection step. Both DR1
and DR4 were tested. In all cases, the inclusion of deter-
gents, urea or an increased temperature, increased the sig-
nal to noise ratios; unfortunately at the cost of overall
signal. The most pronounced signal to noise improve-
ment (about three fold) was obtained with the mildly
denaturing detergent DOC, however, at a concomitant
loss of half the signal. None of these manipulations were
subsequently used.
Peptide titrations were then carried out on the DR mole-
cules, DR1, DR2a and DR4, using optimized α and β
chain concentrations (Figure 6A) followed by the above
described L243-driven ELISA analysis, and curve fitting
the results. The affinities were approximated from the
peptide concentrations leading to half-saturation of the
MHC; the EC50's (Figure 6B). The ELISA-based assay
appeared capable of measuring peptide-binding affinities
for all three DR molecules, and affinities in the low
nanomolar range could be determined. From the titration
curves it is apparent that the HA306–318 peptide gives a
higher Bmax values compared to the CLIP peptide 97–120.
The reason for this is not known, but could be caused by
different complex stabilities affecting the number of com-
plexes surviving the ELISA processing and development
procedures.
High-throughput screening assays of peptide-MHC class II 
binding (direct LOCI)
We have recently developed a HTS assay for peptide-MHC
class I binding using a non-radioactive bead-based
homogenous proximity assay: Luminescent Oxygen
Channeling Immunoassay [13]. As one tag, we used the
biotin group engineered unto the β chain. As the other tag,
we used conformation-dependent MHC class II specific
antibodies (L243 for DR; 9,3F10 for DQ; B7/21 for DP
and 14.4.4s for I-Ed). As for the development of the ELISA,
two-dimensional titrations of MHC class II α and β chain
concentrations were performed and diluted into refolding
buffer containing, or not containing, an excess concentra-
tion of appropriate binding peptide. After 24 h incubation
at 18°C, a mixture of streptavidin-donor beads and anti-
body coupled acceptor beads were added to the reaction
wells and analyzed (see Figure 7). It was evident that pep-
tide-MHC class II complexes required both MHC class II
α and β chains, and were generated in a strictly peptide-
concentration dependent fashion. In this case, optimal αImmunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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and β chain concentrations were found to be around 6 nM
and 1 nM, respectively. Optimal conditions in terms of
whether long or short versions of the different molecules
should be used, at what concentrations the α and β chain
proteins should be used, and the optimal pH were subse-
quently determined (additional file 1, Table 2 and Figure
4). Strikingly, signal to noise ratios observed with the
LOCI technique were consistently better than those
observed with the more traditional ELISA technique (e.g.
compare Figure 5C with Figure 7C).
In some cases, poor signal to noise ratios caused by rather
high background, compromised the direct binding assay
described above. To solve this problem, a competitive
assay was developed using a trace concentration of a
biotin tagged agonist peptide (in casu HA306–318 at 4 nm)
and non-biotinylated β chains molecules. Complex for-
mation was determined using a LOCI assay detecting the
biotinylated peptide with streptavidin donor beads and
the peptide-dependent MHC-II conformation with appro-
priately monoclonal antibody coated acceptor beads. Any
test peptide could now be titrated into a binding reaction
involving the biotinylated agonist peptide and refolding
MHC-II proteins. The resulting inhibition curves could be
fitted by non-linear regression allowing the half maxi-
mum inhibitory concentration, IC50, to be determined
(GrapPad prism, see Materials and Methods). Figure 8
shows affinity measurements of a promiscuous malaria-
derived peptide binding to four different HLA molecules.
To test the direct and competitive assay formats, a panel of
peptides was titrated on different MHC II alleles (Table 1).
The direct and competitive formats were compared for
HLA-DR2a, and found to yield similar results. Note also
that known peptide-MHC-II binding interactions
reported in the literature could be reproduced [26-34].
Discussion
A recombinant approach to generate MHC class II rea-
gents would offer many advantages in the analysis of the
highly polymorphic MHC class II system. These include
ease of production, manipulation, purification, and a
high yield at a modest cost. Since the first report of recom-
binant MHC class II expression was published in 1992,
many different approaches to recombinant MHC class II
production have been suggested and all of them appear to
be in current use i.e. there is no consensus on how to gen-
erate recombinant MHC class II molecules. Many varia-
tions have been tried. E. coli [8,20-22,35-40], insect cells
[36,41-62], yeast cells [63-65], and eukaryotic cells
[66,67] have all been used as production cells. Natural
inter-chain interactions – sometimes including the trans-
membrane domains [51,52,65-67] sometimes excluding
the transmembrane domains (i.e. truncating the chains
after the α2 and β2 domains) [20,36,39,40,43,68,69] –
have been tried. Alternatively, assembly of MHC α and β
chains have been facilitated by phosphatidyl inositol
membrane anchoring [61], by fusion to leucine zippers
[46,49,50,53,63,70-74], by fusion to IgG chains
[42,45,58,75,76], or enforced through the generation of
single chain fusion constructs oriented either as α1 β1- or
β1α1 [37,38,65]. Molecules have been produced in cells
with an intact antigen processing machinery leading to
molecules pre-loaded with a collection of naturally
offered high-affinity binding peptides [77], or in cells
deficient in antigen processing leading to putatively
empty molecules. Alternatively, molecules have been
loaded with a single predefined high-affinity binding pep-
tide fused to the β chain [43,45-47,49,56-58,64,76,78].
These strategies have aimed at improving one or more
aspects of MHC class II production; however, several have
involved principles that significantly limit versatility. Sys-
Competitive peptide-HLA-DR1 binding assay Figure 3
Competitive peptide-HLA-DR1 binding assay. Titra-
tion of peptides and proteins on DR1 using radioactive spun 
column assay. (A) X-axis: Log10 to peptide concentrations in 
nanomolar, Y-axis: percent of offered 125I labelled (Y)Ha306–
318 peptide incorporated into DR1 complexes. 80 nM of urea 
denatured DR1 α and β chain was diluted into refolding 
buffer supplemented with titrations of peptide or protein and 
3 nM 125I labelled YHa306–318 peptide. The following competi-
tors were used: a recombinant version of the extracellular 
part of human invariant chain (positions 73–208), the CLIP 
peptide fragment of the invariant chain (positions 97–120), a 
C-terminal fragment of the invariant chain (positions 118–
208), and the HA306–318 peptide. After 24 h of incubation, 
fractions were analyzed using the spun column assay and IC50 
values (B) determined as described in Materials and Methods. 
All curves fitted with a regression coefficient better than 
0.99. Note that the MHC concentration used (80 nM) bound 
approximately 70–80% of reference peptide (see Figure 2A), 
hence some degree of ligand depletion could be expected.Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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tems that require co-expression of α/β heterodimers limit
utility since cells expressing each α/β combination of
interest will have to be generated one by one. Systems that
require linking of a given peptide to the β chain limit util-
ity since the stable binding of the linked peptide compro-
mises subsequent binding experiments and/or
replacement with any other peptide. Some reported class
II expression systems have had low refolding yields
Disulphide assisted refolding of MHC class II Figure 4
Disulphide assisted refolding of MHC class II. Comparison of disulphide assisted refolding with traditional oxidative 
refolding. (A) Gel shift assay showing that reduction of DRA*0101, DRB5*0101 and DRB1*0401 (by 2-mercaptoethanol (2-
ME)) resulted in formation of a slower moving isomer, and suggesting the presence of oxidized isomers in non-reduced sam-
ples. (B) Urea denatured β chain (4 μM) was reduced in a titration of dithiotreitol (DTT) and diluted 50 times into refolding 
buffer pH 8 containing various redox pairs plus denatured non-reduced α chain and 125I labeled (Y)HA306–318. After 24 h incu-
bation, the experiment was analyzed by spun column assay. X-axis: Concentration of DTT used to reduce β chain; Y-axis: per-
cent of offered 125I labelled (Y)Ha306–318 peptide incorporated into peptide-MHC-II complexes. (black square) No redox pair 
(open circle) Reduced/oxidized glutathione 5/0.5 mM, (black triangle) Reduced/oxidized glutathione 2/2 mM (open square) 
Reduced/oxidized DTT 5/0.5 mM, (cross) Reduced/oxidized DTT 2/2 mM.Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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Checkerboard titrations of DR4 α and β chains analyzed by ELISA Figure 5
Checkerboard titrations of DR4 α and β chains analyzed by ELISA. Various concentrations of urea denatured α and β 
chains were incubated with (A) and without (B) 2 μM HA306–318 in refolding buffer pH 8. After 48 h incubation, the assay was 
analyzed in the sandwich ELISA assay using streptaviding as capture reagent and L243 as detection antibody. (C) Signal to noise 
ratios were calculated from samples with and without HA306–318. In this case, the combination of 31 nM α chain and 1 nM β 
chain was determined to be optimal.Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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[21,22], some associated binding assays have depended
upon a low pH incubation to release endogenous pep-
tides [6,79-83], and others have had to use high concen-
trations of reporter peptide to detect interaction thus
precluding detection of high-affinity interactions
[66,73,80-82,84-87].
Protein expression systems based upon E. coli expression
are potentially fast, versatile and high-yield. Unfortu-
nately, it would appear that many attempts to express
class II in E. coli have failed [88]. Major drawbacks of E.
coli expression include lack of proper folding, disulfide
bond formation, and glycosylation leading to aggregate
deposition of these non-functional proteins in inclusion
bodies. However, a few class II molecules, capable of
binding any appropriate peptide offered, have already
been successfully produced as isolated subunits in E. coli
(DR1 [20,22], DR2a [8] DR4 [89] and I-Ek [21]). This
demonstrates that it might be possible to express the two
chains as isolated subunits and recombine them to gener-
ate any desired heterodimer capable of binding any
appropriate peptide. This should lead to considerable sav-
ings, in particular for DP and DQ molecules, where a lim-
ited number of α and β chains can be combined to
generate thousands of different receptors. Here, we illus-
trate this latter point by making HLA-DP and DQ mole-
cules composed of polymorphic α chains (DP1A*0301
and DQA1*0501) paired with the polymorphic β chains
(DPB1*0401 and DQB1*0201) respectively.
Here, we have generated an efficient E. coli -based expres-
sion system for MHC class II molecules. Our approach to
E. coli production of MHC class II molecules differs in sev-
eral respects from those described in the literature. We
have used dimerizing modules to facilitate class II α/β
pairing and refolding. To the best of our knowledge this
has never before been attempted for class II molecules
produced in E. coli . We have also used a pre-oxidized
ELISA-based peptide-MHC class II binding assay Figure 6
ELISA-based peptide-MHC class II binding assay. Urea denatured α and β chains of DR1, DR2 and DR4 were diluted 
into titrations of CLIP or HA306–318 peptides in refolding buffer pH 8 (final concentrations of α and β chains were 31 and 2; 31 
and 1; and 31 and 1 nM, respectively). After 24 h incubation at 18°C, the assay was developed as described in materials and 
methods. The measurements were background subtracted and analysed in Graphpad Prism as previously described. (A) Satura-
tion curve for (black triangle) HA306–318 and (black square) CLIP binding to DR1 (left hand panel), DR2 (middle panel) or DR4 
(right hand panel) plotted as Absorbance at 450 nm versus the logarithm(10) of the peptide concentration in nM. (B) EC50 val-
ues and signal to noise ratios (calculated as the ratio between signal at maximum peptide concentration and background). Not 
determined (N.D.).Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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Checkerboard titrations of DR4 α and β chains analyzed by LOCI Figure 7
Checkerboard titrations of DR4 α and β chains analyzed by LOCI. Various concentrations of urea denatured α and β 
chains incubated with (A) and without (B) 2 μM HA306–318 in refolding buffer pH 8. After 48 h of incubation, the assay was ana-
lyzed by LOCI using L243 antibody coupled to acceptor beads and streptavidin coupled donor beads. (C) Signal to noise ratios 
were calculated from samples with and without HA306–318. In this case, concentrations of 6.3 nM α chains and 1.3 nM β chains 
were determined to be optimal.Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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refolding principle. To our knowledge, all past attempts at
producing class II in E. coli have involved extraction of
class II proteins from inclusion bodies using denaturant
solutions containing a reducing agent followed by refold-
ing by dilution into a buffer containing a suitable redox
pair to facilitate disulphide bond formation. Such refold-
ing approaches are frequently plagued by low yields. We
have successfully produced functional class I molecules in
high yield from E. coli exploiting the fact that correctly pre-
oxidized class I heavy chain molecules can be extracted
from inclusion bodies in the absence of reducing agents
(note, we don't know whether these disulfide bonds are
generated in vivo in the bacteria, or in vitro during the pro-
tein extraction process). Upon dilution into refolding
buffer such pre-oxidized class I molecules refolds rapidly
and completely. Indeed, our preparations of MHC class II
α and β chain proteins contain pre-oxidized species, and
they appear essential for the efficiency of the refolding
process. We speculate that this is the main reason why all
nine MHC class II molecules, that we have produced, have
Direct and competitive LOCI-based peptide-MHC-II binding assay Figure 8
Direct and competitive LOCI-based peptide-MHC-II binding assay. Titrations on a promiscuous malaria derived pep-
tide YILLKKILSSRFNQM DR4: KD = 133 nM R2 = 0.98. DP401: KD = 0.8 nM R2 = 0.99. I-Ed: KD = 14 nM R2 = 0.98. DR2a: inhi-
bition assay, reference peptide 4 nM Biotin-PEG-HA306–318 IC50 = 0.6 nM R2 = 0.98.Immunome Research 2009, 5:2 http://www.immunome-research.com/content/5/1/2
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been successfully refolded and been useful in studies
involving binding of soluble peptide.
One of our primary motivations to generate recombinant
MHC class II molecules is to examine their peptide bind-
ing specificity and eventually generate accurate predictors
of this event. To this end, biochemical assays should be
able to provide large amounts of detailed quantitative
binding information. Initially, we developed a standard
assay detecting binding of radio-labeled peptide by gel fil-
tration, and used this to systematically vary a number of
parameters such as refolding additives, pH, temperature
and time etc. A few parameters seemed universally benefi-
cial; most pronounced was the addition of glycerol to the
refolding buffer. Stern et al have also noticed this [20].
Other parameters such as length (i.e. where to truncate the
α and β chains, additional file 1, Figure 4) and pH were
more variable and had to be optimized for each MHC
class II heterodimer in question.
Ideally, high-throughput binding assays should be devel-
oped to deal with the large number of potential peptide-
MHC class II combinations of interest. In the additional
information, we demonstrate that a homogenous Scintil-
lation Proximity Assay (SPA) is an attractive high-
throughput method for those who consider assays based
upon radioactivity as an option. We have also developed
assays that do not depend upon radioactivity. One is
based on the interaction of the peptide-MHC combina-
tion in question followed by a standardized sandwich
ELISA to measure the concentration of bound peptide.
This can be implemented in most laboratories and yields
robust results capable of measuring binding affinities in
the low nM range. We have recently developed a non-radi-
oactive, high-throughput homogenous assay for peptide-
MHC class I interaction[13]. This assay is based upon
Luminescent Oxygen Channeling Immunoassay (LOCI).
Here, we demonstrate that this detection mode also works
for peptide-MHC class II. In fact, the signal to noise ratio
is even better for the LOCI-based assay than it is for the
ELISA based assay. The LOCI-based assay has been auto-
mated for large-scale screening for MHC class II restricted
epitopes (Table 1).
Conclusion
We have generated a method to produce functional MHC
II molecules from pre-oxidized, leucine zipper fused α
and β chains individually produced in E. Coli. This proto-
col is particularly useful when addressing the polymor-
phic nature of HLA-DP and DQ molecules as
demonstrated by the refolding of functional HLA com-
plexes from individually produced α and β chains. Several
peptide binding assays were developed including a high-
throughput peptide-binding assay based on the homoge-
nous assay platform LOCI. The developed protocols
should provide valuable tools to study MHC II function
and can be used to generate data for the training of accu-
rate bioinformatics based prediction tools.
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